Nervgen Pharma ratios data for the quarter ended Jun 2026. These financial ratios cover 5 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2024 | Mar2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|
| Efficiency | |||||
| Assets AverageAssets Avg. | 15.89M | 40.17M | |||
| Invested CapitalInvested Cap. | 1.91M | 2.50M | |||
| Leverage & Solvency | |||||
| Debt Ratio | 0.00 | 0.00 | |||
| Valuation | |||||
| Price to EarningsP/E | -51.12 | -245.76 | |||
| Price to BookP/B | 83.13 | 178.90 | 74.31 | 13.14 | |
| Enterprise Value | 140.96M | 140.67M | 430.20M | 288.20M | 101.33M |
| Market Capitalization | 153.33M | 140.67M | 446.04M | 300.28M | 164.08M |